Show simple item record

dc.contributor.advisorHersh, Evan M.en_US
dc.contributor.authorHuynh, Wally Chau
dc.creatorHuynh, Wally Chauen_US
dc.date.accessioned2013-05-09T11:23:02Z
dc.date.available2013-05-09T11:23:02Z
dc.date.issued2001en_US
dc.identifier.urihttp://hdl.handle.net/10150/290456
dc.description.abstractTumor specific antigens are the holy grails of cancer research. We made an attempt to identify novel tumor antigens by examining the tumor infiltrating B lymphocyte (TIL-B), and lymph node derived B cell (LN-B) population. TIL-B and LN-B cells were tested for reactivity against glutaraldehyde-fixed allogeneic cell lines by enzyme linked immunosorbant assay (ELISA). Of the 466 wells containing TIL-B cells, 29 (6.2%) of them produced antibodies that were reactive to allogeneic tumor cell lines. Of the 712 wells containing LN-B cells, 79 (11.1%) of them produced reactive antibodies to allogeneic tumor cell lines. Unfortunately, we were unable to identify specific clones producing those reactive antibodies by limiting dilution. Furthermore, we examined the murine immune response to a truncated p53 harboring four point mutations and fused to enhanced green fluorescent protein (EGFP). Balb/c mice were immunized with either plasmid DNA or the recombinant protein. We found that delivery by intramuscular injection of plasmid DNA encoding truncated, mutant p53 along with murine GM-CSF mice resulted in non-measurable antibody response and minimal cellular cytotoxic activity while recombinant protein immunization resulted in a strong antibody response and no measurable cytotoxic activity. We conclude that immunization with the fusion construct containing green fluorescent protein does not enhance cytotoxic responses to mutant p53. In addition, the creation of multiple point mutations in the p53 gene may have prevented the fusion protein from being processed and expressed on MHC class I molecules.
dc.language.isoen_USen_US
dc.publisherThe University of Arizona.en_US
dc.rightsCopyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.en_US
dc.subjectHealth Sciences, Immunology.en_US
dc.subjectHealth Sciences, Oncology.en_US
dc.titleTumor antigens: From discovery to vaccineen_US
dc.typetexten_US
dc.typeDissertation-Reproduction (electronic)en_US
thesis.degree.grantorUniversity of Arizonaen_US
thesis.degree.leveldoctoralen_US
dc.identifier.proquest3023492en_US
thesis.degree.disciplineGraduate Collegeen_US
thesis.degree.disciplineCancer Biologyen_US
thesis.degree.namePh.D.en_US
dc.identifier.bibrecord.b41957490en_US
refterms.dateFOA2018-08-29T18:44:02Z
html.description.abstractTumor specific antigens are the holy grails of cancer research. We made an attempt to identify novel tumor antigens by examining the tumor infiltrating B lymphocyte (TIL-B), and lymph node derived B cell (LN-B) population. TIL-B and LN-B cells were tested for reactivity against glutaraldehyde-fixed allogeneic cell lines by enzyme linked immunosorbant assay (ELISA). Of the 466 wells containing TIL-B cells, 29 (6.2%) of them produced antibodies that were reactive to allogeneic tumor cell lines. Of the 712 wells containing LN-B cells, 79 (11.1%) of them produced reactive antibodies to allogeneic tumor cell lines. Unfortunately, we were unable to identify specific clones producing those reactive antibodies by limiting dilution. Furthermore, we examined the murine immune response to a truncated p53 harboring four point mutations and fused to enhanced green fluorescent protein (EGFP). Balb/c mice were immunized with either plasmid DNA or the recombinant protein. We found that delivery by intramuscular injection of plasmid DNA encoding truncated, mutant p53 along with murine GM-CSF mice resulted in non-measurable antibody response and minimal cellular cytotoxic activity while recombinant protein immunization resulted in a strong antibody response and no measurable cytotoxic activity. We conclude that immunization with the fusion construct containing green fluorescent protein does not enhance cytotoxic responses to mutant p53. In addition, the creation of multiple point mutations in the p53 gene may have prevented the fusion protein from being processed and expressed on MHC class I molecules.


Files in this item

Thumbnail
Name:
azu_td_3023492_sip1_m.pdf
Size:
3.090Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record